Clinical Trial Update: PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial compares a PD-1 antibody to best supportive care following chemoradiation in locoregionally advanced nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma
• Nasopharyngeal Neoplasms

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING